

## **Education**

MS, V.N. Karazin Kharkiv National University, Ukraine  
PhD, University of Pittsburgh

## **Courses**

BIOST 2043: Introduction to Statistical Theory I  
BIOST 2044: Introduction to Statistical Theory II

## **Publications**

Mamounas EP, **Bandos H**, Lembersky BC, Jeong JH, Geyer Jr CE, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, and Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomized, double-blind, placebo-controlled phase 3 trial. *The Lancet Oncology*. 2019; 20: 88-99. PMID: 30509771

Kim RS, Song N, Gavin PG, Salgado R, **Bandos H**, Kos Z, Floris G, Eynden GGVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Lawrence Wickerham D, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. *J Natl Cancer Inst*. 2019 [Epub ahead of print]. PMID: 30888406

Gunn CM, Bokhour BG, Parker VA, Battaglia TA, Parker PA, Fagerlin A, McCaskill-Stevens W, **Bandos H**, Blakeslee SB, Holmberg C. Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1. *Med Decis Making*. 2019; 39(3):217-227. PMID 30803311

**Bandos H**, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL, III, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term effects of adjuvant chemotherapy on peripheral neuropathy in patients with early-stage breast cancer: Secondary analysis of NRG Oncology/NSABP B-30. *J Natl Cancer Inst*. 2018; 110(2). PMID: 28954297

Rivera DR, Ganz PA, Weyrich MS, **Bandos H**, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients with Early- Stage Breast Cancer: A Systematic Review of Long-Term Adverse Effects. *J Natl Cancer Inst*. 2018; 110 (2). PMID: 28954296

Holmberg C, **Bandos H**, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ. Results from NRG Oncology/NSABP protocol DMP-1: women's decision-making in breast cancer risk reduction. *Cancer Prevention Research*. 2017; 10(11): 625-634. PMID: 28978566

Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, **Bandos H**, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C. Deciding on breast cancer risk reduction: the role of counseling in individual decision-making – a qualitative study. *Patient Education and Counseling*. 2017; 100(12): 2346-2354. PMID: 28734560

Gunn CM, Bokhour B, Parker VA, Parker PA, **Bandos H**, Holmberg C. Exploring explanatory models of risk in breast cancer risk counseling discussions. *Cancer Nursing*. 2017 [Epub ahead of print]. PMID: 28661894

Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, **Bandos H**, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong, JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL. Association of Polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer analysis of the NSABP B-31 trial. *JAMA Oncology*. 2017; 3(3):335-341. PMID: 27812689

Jatoi I, **Bandos H**, Jeong JH, Anderson WF, Romond EH, Mamounas EP, Wolmark N. Time-varying effects of breast cancer adjuvant systemic therapy. *J Natl Cancer Inst* 2015 108(1): PMID: 26518884

Klepin HD, Geiger AM, **Bandos H**, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive factors associated with adherence to oral anti-estrogen therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene Study. *Cancer Prevention Research*. 2014 Jan;7(1):161-168. PMID: 24253314

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, **Bandos H**, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE, Costantino JP, Wolmark N, Paik S. Predicting Degree of Benefit from Adjuvant Trastuzumab in NSABP Trial B-31. *Journal of the National Cancer Institute*. 2013 Dec 4;105(23):1782-8. PMID: 24262440

Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, **Bandos H**, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. *The Lancet Oncology* 2013, 14 (12): 1183-1192. PMID: 24095300

Danhauer SC, Legault C, **Bandos H**, Kidwell K, Costantino J, Vaughan L, Avis NE, Rapp S, Coker LH, Naughton M, Naylor C, Terracciano A, Shumaker S. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. *Aging, neuropsychology and cognition: a journal on normal dysfunctional development*, 2013; 20(5):532-52. PMID: 23237718

Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, **Bandos H**, Weissfeld JL, Wolmark N. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). *Cancer Prevention Research*. 2012, 5 (11):1321-1329. PMID:23060039

Jung S, Jeong JH, **Bandos H**. Regression on quantile residual life. *Biometrics*. 2009, 65: 1203-1212. PMID:19432781

Fisher ER, Costantino JP, Leon ME, **Bandos H**, Palekar AS, Fisher B, Wolmark N. Pathobiology of small invasive breast cancer without metastases (T1a/b, NO, MO). National Surgical Adjuvant Breast and Bowel Project (NSABP). Protocol B-21. *Cancer*. 2007, November 1. 110(9): 1929-1936. PMID:17896781